Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.87 |
| ▸ | TUBB | P07437 | 4/20 | 0.87 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.87 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.87 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.87 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.87 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.87 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.87 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.87 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.87 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.87 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.87 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.87 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.87 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | P4HB | P07237 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mertansine SCHEMBL21095214 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24235209 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22762724 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22097295 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24776847 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24917414 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24823366 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24336892 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL23140493 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22580840 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230287137-A1 | CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11744900-B2 | Preparation of maytansinoid antibody conjugates by a one-step process | IMMUNOGEN, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230181755-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL | SANOFI (FR) | 2023-06-15 | — | — | US | disclosed |
| WO-2023099683-A1 | CEA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY | SANOFI (FR) | 2023-06-08 | — | — | WO | disclosed |
| US-20230158168-A1 | PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES | IMMUNOGEN, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230149557-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND CETUXIMAB | SANOFI (FR) | 2023-05-18 | — | — | US | disclosed |
| US-20230151088-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFOX | SANOFI (FR) | 2023-05-18 | — | — | US | disclosed |
| WO-2023079057-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES AND ANTI-VEGFR-2 ANTIBODIES | SANOFI (FR) | 2023-05-11 | — | — | WO | disclosed |
| US-11471536-B2 | Process for preparing purified drug conjugates | IMMUNOGEN, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-7342110-B2 | Polynucleotides, host cells and vectors for antibodies against leukemia CD 33 antigen | IMMUNOGEN INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342110-B2 | Polynucleotides, host cells and vectors for antibodies against leukemia CD 33 antigen | IMMUNOGEN INC. (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2008010101-A2 | ANTAGONIST ANTIBODY AGAINST EPHA2 FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007024536-A2 | PROCESS FOR PREPARING MAYTANSINOID ANTIBODY CONJUGATES | IMMUNOGEN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070048314-A1 | preparing a cell-binding agent chemically coupled to a drug; covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step; high purity and stability | IMMUNOGEN, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070048314-A1 | preparing a cell-binding agent chemically coupled to a drug; covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step; high purity and stability | IMMUNOGEN, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024222-A1 | A CA6 ANTIGEN-SPECIFIC CYTOTOXIC CONJUGATE AND METHODS OF USING THE SAME | IMMUNOGEN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070041980-A1 | using the conjugates in the inhibition of cell growth; cancer; monoclonal antibody or epitope-binding fragment thereof, that recognizes and binds the CA6 glycotope | IMMUNOGEN INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2007019232-A2 | IMMUNOCONJUGATE FORMULATIONS | IMMUNOGEN, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070031402-A1 | Immunoconjugate formulations | IMMUNOGEN INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070048314-A1 | preparing a cell-binding agent chemically coupled to a drug; covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step; high purity and stability | EPCAM, VCAM1, CD44 | TUBB4A 104/4885TUBB 163/4885TUBA3C 469/4885 |
| US-20230158168-A1 | PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES | EPCAM, CD44, NAPA | TUBB4A 139/4885TUBB 254/4885TUBA3C 357/4885 |
| US-20230181755-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL | TAS2R5, TMEM205, CD99 | TUBB4A 853/4885TUBB 690/4885TUBA3C 348/4885 |
| US-20070041980-A1 | using the conjugates in the inhibition of cell growth; cancer; monoclonal antibody or epitope-binding fragment thereof, that recognizes and binds the CA6 glycotope | CA6, CA14, CA13 | TUBB4A 3340/4885TUBB 4079/4885TUBA3C 2911/4885 |
| US-20230151088-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND FOLFOX | FOLR1, FOLR2, ITGA5 | TUBB4A 1258/4885TUBB 1089/4885TUBA3C 742/4885 |
| US-20230149557-A1 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES AND CETUXIMAB | EPCAM, CA13, CA14 | TUBB4A 1543/4885TUBB 2006/4885TUBA3C 714/4885 |
| US-20070031402-A1 | Immunoconjugate formulations | CD44, SLC6A5, SI | TUBB4A 2623/4885TUBB 1517/4885TUBA3C 1768/4885 |
| US-11744900-B2 | Preparation of maytansinoid antibody conjugates by a one-step process | CD47, CD22, CLSPN | TUBB4A 1345/4885TUBB 2767/4885TUBA3C 2822/4885 |
| US-20230287137-A1 | CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOF | SIGLEC7, CD2BP2, FUT7 | TUBB4A 1423/4885TUBB 1677/4885TUBA3C 1810/4885 |
| US-11471536-B2 | Process for preparing purified drug conjugates | EPCAM, CD44, NAPA | TUBB4A 139/4885TUBB 254/4885TUBA3C 357/4885 |
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | FCGRT, FCGR1A, FCGR3B | TUBB4A 1047/4885TUBB 798/4885TUBA3C 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.